Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PHI

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    82 result(s) found for: PHI. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2004-004384-29 Sponsor Protocol Number: Levosepsis1 Start Date*: 2005-05-23
    Sponsor Name:Dr GED DEMPSEY, University Hospital Aintree
    Full Title: Double blind randomised controlled trial of Levosimendan versus Dopexamine in septic shock
    Medical condition: Septic Shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000554-19 Sponsor Protocol Number: P25-INACTION Start Date*: 2017-10-12
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Implication for strategies of long term control of viral replication in patient with primary HIV infection (PHI) treated with multitarget antiviral therapy (MT-ART)
    Medical condition: subject whith PHI never treated
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10000807 Acute HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022921-13 Sponsor Protocol Number: AUX-CC-802 Start Date*: 2011-01-24
    Sponsor Name:Auxilium UK Limited
    Full Title: A PHASE 3, OPEN-LABEL STUDY OF THE SAFETY AND EFFECTIVENESS OF AA4500 ADMINISTERED TWICE PER TREATMENT CYCLE FOR UP TO FOUR TREATMENT CYCLES (2 x 4) IN MEN WITH PEYRONIE’S DISEASE
    Medical condition: Peyronie's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10034765 Peyronie's disease PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) DK (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021978-11 Sponsor Protocol Number: 101MS326 Start Date*: 2011-05-04
    Sponsor Name:Biogen Idec Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis
    Medical condition: Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) FI (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) ES (Completed) PL (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002270-39 Sponsor Protocol Number: 205270 Start Date*: 2018-02-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 28-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center, study in recombinant human erythropoietin (rhEPO) naïve non-dialysis participants with anemia associated with ...
    Medical condition: Anaemia associated with chronic kidney disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-024477-39 Sponsor Protocol Number: 105MS302 Start Date*: 2011-05-06
    Sponsor Name:Biogen Idec Limited
    Full Title: A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BE (Completed) DE (Completed) ES (Completed) BG (Completed) EE (Completed) GB (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-001312-30 Sponsor Protocol Number: Start Date*: 2019-04-30
    Sponsor Name:Common Services Agency
    Full Title: SPRING - Seizure PRophylaxis IN Glioma
    Medical condition: Seizures in patients with suspected cerebral glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061030 Brain tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-000509-31 Sponsor Protocol Number: 206-OC-202 Start Date*: 2007-10-10
    Sponsor Name:Biogen Idec Ltd
    Full Title: Estudio en fase 1/2, abierto, adaptativo, aleatorio de doxorrubicina liposómica con o sin M200 (volociximab) para el tratamiento de pacientes con cáncer de ovario epitelial avanzado o cáncer perito...
    Medical condition: Cáncer de ovario epitelial avanzado o cáncer peritoneal primario Advanced epithelial ovarian cancer or primary peritoneal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005592-14 Sponsor Protocol Number: 26 Start Date*: 2006-07-27
    Sponsor Name:IFSgGmbH, Institute for clinical research
    Full Title: Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PRO...
    Medical condition: Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000542-65 Sponsor Protocol Number: 200808 Start Date*: 2016-11-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to ...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) AT (Prematurely Ended) CZ (Completed) DE (Completed) PT (Completed) SE (Completed) ES (Completed) NL (Completed) BG (Completed) GR (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003696-12 Sponsor Protocol Number: 109MS301 Start Date*: 2007-03-02
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) AT (Completed) SE (Prematurely Ended) NL (Completed) GR (Completed) IT (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002070-35 Sponsor Protocol Number: MUC_NewEra_3.1 Start Date*: 2009-05-13
    Sponsor Name:MUC Research GmbH
    Full Title: NEW ERA STUDY HIV and Eradication: A multicenter, open-label, non-randomized trial to evaluate treatment with multi-drug class (MDC) HAART and its impact on the decay rate of latently infected...
    Medical condition: Human immuno-deficiency virus [HIV] disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10020160 HIV disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004753-14 Sponsor Protocol Number: 109MS303 Start Date*: 2009-01-22
    Sponsor Name:Biogen Idec Limited
    Full Title: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) DE (Completed) IE (Completed) LV (Completed) ES (Completed) FR (Completed) EE (Completed) GR (Completed) AT (Completed) NL (Completed) BG (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000541-31 Sponsor Protocol Number: 200807 Start Date*: 2016-12-02
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evalu...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) DE (Completed) SE (Completed) PT (Completed) ES (Completed) NL (Completed) AT (Completed) GR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007395-42 Sponsor Protocol Number: 160HF301 Start Date*: 2008-09-25
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess The Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insuffic...
    Medical condition: Acute Decompensated Heart Failure and Renal Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed) IT (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003176-39 Sponsor Protocol Number: 205MS303 Start Date*: 2013-05-31
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) CZ (Completed) HU (Completed) PL (Completed) SE (Completed) ES (Completed) IE (Prematurely Ended) GB (Completed) FI (Prematurely Ended) GR (Completed) FR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-003697-10 Sponsor Protocol Number: 109MS302 Start Date*: 2007-04-13
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IE (Completed) GR (Completed) EE (Completed) LV (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001642-10 Sponsor Protocol Number: SMT19969/C005 Start Date*: 2019-03-13
    Sponsor Name:Summit (Oxford) Limited
    Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ...
    Medical condition: Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) LT (Completed) BE (Prematurely Ended) DE (Completed) CZ (Completed) ES (Ongoing) FR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-002701-38 Sponsor Protocol Number: AT1001-042 Start Date*: 2014-12-17
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: An Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in subjects with Fabry Disease
    Medical condition: Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the gene (GLA) that encodes the lysosomal enzyme a-galactosidase A.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001641-27 Sponsor Protocol Number: SMT19969/C004 Start Date*: 2019-07-05
    Sponsor Name:Summit (Oxford) Limited
    Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ...
    Medical condition: Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GR (Prematurely Ended) BG (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 20:33:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA